Mechanisms underlying differential expression of interleukin-8 in breast cancer cells.

(1)

HAL Id: inserm-00143639

https://www.hal.inserm.fr/inserm-00143639

Submitted on 27 Apr 2007

HAL is a multi-disciplinary open access

archive for the deposit and dissemination of sci-entific research documents, whether they are pub-lished or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Mechanisms underlying differential expression of

interleukin-8 in breast cancer cells.

Ariane Freund, Valérie Jolivel, Sébastien Durand, Nathalie Kersual, Dany

Chalbos, Carine Chavey, Françoise Vignon, Gwendal Lazennec

To cite this version:

Ariane Freund, Valérie Jolivel, Sébastien Durand, Nathalie Kersual, Dany Chalbos, et al.. Mechanisms underlying differential expression of interleukin-8 in breast cancer cells.. Oncogene, Nature Publishing Group, 2004, 23 (36), pp.6105-14. �10.1038/sj.onc.1207815�. �inserm-00143639�

(2)

IL8 ng/ml/mil lion Cell s/ 48h

0

200

400

600

800 1000

1200

NT IL1 α IL1 β TNF α

MDA-MB-231

Fig. 1

NT IL1 α IL1 β TNF α

MCF-7

0

40

80

120

160

200

(3)

A

D

B

Fig. 2

MDA-MB-2

3

1 MCF-7

IL-8

rS9

0 20 40 60 80 100 MDA-MB-231 MCF-7 IL-8 tr a n s c ri p tion r a te

xp2

xp2-IL8 xp2-IL8 AS

MCF-7

MDA-MB-231

IL8 RNA l e v e ls

0 5000

10000

15000

20000

25000

Xp 2-IL-8 / Xp2 rat io 0 100 200 300 400 500 600 700 MDA-MB-231 MDA-MB-436 CAMA-1 MCF-7 100 200 300 400 0 MDA-MB-231 MDA-MB-436 IL 8 n g /ml/ m illi o n Ce ll s /4 8 h CAMA-1 MCF-7

C

0 20 40 60 80 100 MDA-MB-231 MCF-7 R e la ti v e L u c if e rase Ac ti v it y

(4)

-27

2 -98

-50

04

0

0 8000

12000

1 6000

20000

Relative LUC

Activity

_MDA-MB-231

MCF-7

-1

481

AP-1 C/EB P NF-κB LUC

Fig. 3

(5)

LUC -1481 AP-1 C/EBP NF-κB MDA-MB-231 MCF-7 0 4000 8000 12000 16000

Relative LUC Activity

MCF-7

MDA-MB-231

+

1 2 3

+

1 2 3

+

1 2 3

AP-1

C/EBP

NF-κB

-1481 AP-1 C/EBP NF-κB -1481 AP-1 C/EBP NF-κB -1481 AP-1 C/EBP NF-κB -1481 AP-1 C/EBP NF-κB -1481 AP-1 C/EBP NF-κB -1481 AP-1 C/EBP NF-κB -1481 AP-1 C/EBP NF-κB

X

Fig. 4

A

B

LUC LUC LUC LUC LUC LUC LUC

MCF-7

MDA-MB-2

3

1

HDAC-1

(6)

Fig. 5

C/EBP

δ

C/EBP

β

NF-κB

C/EBP

α

-MDA-MB-231

C

Ab

Comp

A

B

c-Jun

Fra-1

Fra-2

C/EBP

AP-1

c-fos

-MDA-MB-231

C

Ab

Comp

C

1

2

3

4

5

6

7

8 p65

c-Rel

p52

AP-1

NF-κB

p50

-MDA-MB-231

C

Ab

Comp

RelB

9 D

C/EBP

β

C/EBP

α

p50

p65

Fra-1

Fra-2

c-Jun

Actin

M C F -7 M D A -M D -23 1

(7)

0 5000

10000

15000

20000

25000

C

JDP-1

JDP-2 Tam67

Relative LUC

Activity

MDA-MB-231

MCF-7

AP1-TK-CAT

MDA-MB-231

MCF-7

0

20

40

60

80

100 Relative CAT Activity

Fig. 6

A

(8)

MCF-7

MDA-MB-231

Relative LUC Activity

NFκB-LUC 0 4000 8000 12000 16000 20000

Fig. 7

A

B

MDA-MB-231

MCF-7

0 5000

10000

15000

20000

25000

Ad5

Ad-IκB

Re la tiv e LU C A c tiv it y

C

0 4000 8000 12000 16000 xp2-IL-8 NFκB-LUC Relative LUC activ it y control E2 ER ER + E2 0 20 40 60 80 100 120 AP1-TK-CAT Relative CAT act iv ity